Anti-Notch3 antibodies and antibody-drug conjugates
US-9433687-B2 · Sep 6, 2016 · US
Antibodies against notch 3
US10538587B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10538587-B2 |
| Application number | US-201514853003-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 14, 2015 |
| Priority date | Mar 14, 2013 |
| Publication date | Jan 21, 2020 |
| Grant date | Jan 21, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to antibodies or fragments thereof that target at least one conformational epitope of a Notch 3 or mutant Notch 3 receptor; and compositions and methods of use thereof.
First claim
Opening claim text (preview).
We claim: 1. An isolated antibody that binds to Notch 3 or a Notch3 binding fragment thereof, wherein the antibody or fragment comprises: a heavy chain variable region comprising the CDR1 amino acid sequence of SEQ ID NO: 23; the CDR2 amino acid sequence of SEQ ID NO: 24; the CDR3 amino acid sequence of SEQ ID NO: 25; and a light chain variable region comprising the CDR1 amino acid sequence of SEQ ID NO: 33; the CDR2 amino acid sequence of SEQ ID NO: 34; and the CDR3 amino acid sequence of SEQ ID NO: 35. 2. The isolated antibody or fragment thereof of claim 1 , comprising a variable heavy chain sequence and a variable light chain sequence selected from the group consisting of: a variable heavy chain sequence having the amino acid sequence of SEQ ID NO:29 and a variable light chain sequence having the amino acid sequence of SEQ ID NO: 39. 3. A pharmaceutical composition comprising the antibody or fragment thereof of claim 1 and a pharmaceutically acceptable carrier. 4. The isolated antibody or fragment thereof of claim 1 , wherein the antibody is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a humanized antibody, and a synthetic antibody. 5. A single chain antibody that binds to Notch3 or a Notch 3 binding fragment thereof, wherein the antibody or fragment comprises: a heavy chain variable region comprising the CDR1 amino acid sequence of SEQ ID NO:23; the CDR2 amino acid sequence of SEQ ID NO: 24; the CDR3 amino acid sequence of SEQ ID NO: 25; a light chain variable region comprising the CDR1 amino acid sequence of SEQ ID NO: 33; the CDR2 amino acid sequence of SEQ ID NO: 34; and the CDR3 amino acid sequence of SEQ ID NO: 35. 6. The single chain antibody or fragment thereof of claim 5 , comprising a variable heavy chain sequence having the amino acid sequence of SEQ ID NO: 29 and a variable light chain sequence having the amino acid sequence of SEQ ID NO: 39.
Assignees
Inventors
Classifications
specific for leukemia · CPC title
Antineoplastic agents · CPC title
F(ab')2 · CPC title
specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor · CPC title
Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10538587B2 cover?
- The present disclosure relates to antibodies or fragments thereof that target at least one conformational epitope of a Notch 3 or mutant Notch 3 receptor; and compositions and methods of use thereof.
- Who is the assignee on this patent?
- Deplazes Lauber Joelle, Fryer Christy, Hu Tiacen, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/28. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).